晚期癌症患者入住专科姑息治疗单元时股静脉深静脉血栓的患病率、症状负担与自然病史(HIDDen):一项前瞻性纵向观察研究
该研究在英格兰、威尔士和北爱尔兰的5个专科姑息治疗单元连续纳入343例晚期癌症成人,入院时及每周行双侧股静脉超声检查至死亡或出院(最长3周)。273例可评估扫描中92例(34%,95%CI 28-40)存在股静脉深静脉血栓;既往静脉血栓栓塞、过去12周内因任何原因卧床及下肢水肿独立预测深静脉血栓,而血栓预防、生存期及除腿水肿外的症状与深静脉血栓无关。
要点
- 晚期癌症患者入住专科姑息治疗单元时股静脉深静脉血栓患病率约三分之一(34%,95%CI 28-40)。
- 既往静脉血栓栓塞、过去12周内卧床、下肢水肿独立预测股静脉深静脉血栓。
- 血栓预防、生存期及除腿水肿外的症状与股静脉深静脉血栓无关。
核心结论
- 约三分之一的晚期癌症患者入住专科姑息治疗单元时存在股静脉深静脉血栓。
- 深静脉血栓与血栓预防、生存期或除腿水肿外的症状无关。
- 这些发现与静脉血栓栓塞是晚期疾病的表现而非过早死亡的原因相一致。
- 对于体能状态差的专科姑息治疗单元住院患者,血栓预防似乎获益甚微。
研究设计与样本
- 前瞻性纵向观察研究,在英国英格兰、威尔士和北爱尔兰的5个专科姑息治疗单元(4个临终关怀院和1个姑息治疗单元)进行。
- 连续纳入成人癌症患者,入院时及每周行双侧股静脉超声检查直至死亡或出院,最长3周。
- 排除估计预后短于5天的患者;主要终点为入住专科姑息治疗单元48小时内股静脉深静脉血栓的患病率,按意向治疗分析。
- 研究注册号ISRCTN97567719;2016年6月20日至2017年10月16日共纳入343例参与者。
主要发现
- 343例参与者平均年龄68.2岁(SD 12.8;范围25-102),179例(52%)为男性,平均澳大利亚改良Karnofsky体能状态评分49(SD 16.6;范围20-90)。
- 273例可评估扫描中,92例(34%,95%CI 28-40)存在股静脉深静脉血栓。
- 4例入院时扫描无深静脉血栓的参与者在21天内重复扫描时出现深静脉血栓。
- 既往静脉血栓栓塞(p=0.014)、过去12周内因任何原因卧床(p=0.003)和下肢水肿(p=0.009)独立预测深静脉血栓。
- 血清白蛋白浓度(p=0.43)、血栓预防(p=0.17)和生存期(p=0.45)与深静脉血栓无关。
临床怎么用
- 作者认为,对于体能状态差的专科姑息治疗单元住院患者,血栓预防似乎获益甚微。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of deep venous thrombosis in patients with advanced cancer is unconfirmed and it is unknown whether current international thromboprophylaxis guidance is applicable to this population. We aimed to determine prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist palliative care units (SPCUs). METHODS: We did this prospective longitudinal observational study in five SPCUs in England, Wales, and Northern Ireland (four hospices and one palliative care unit). Consecutive adults with cancer underwent bilateral femoral vein ultrasonography on admission and weekly until death or discharge for a maximum of 3 weeks. Data were collected on performance status, attributable symptoms, and variables known to be associated with venous thromboembolism. Patients with a short estimated prognosis (<5 days) were ineligible. The primary endpoint of the study was the prevalence of femoral deep vein thrombosis within 48 h of SPCU admission, analysed by intention to treat. This study is registered with the ISRCTN registry, number ISRCTN97567719. FINDINGS: Between June 20, 2016, and Oct 16, 2017, 343 participants were enrolled (mean age 68·2 years [SD 12·8; range 25-102]; 179 [52%] male; mean Australian-modified Karnofsky performance status 49 [SD 16·6; range 20-90]). Of 273 patients with evaluable scans, 92 (34%, 95% CI 28-40) had femoral deep vein thrombosis. Four participants with a scan showing no deep vein thrombosis on admission developed a deep vein thrombosis on repeat scanning over 21 days. Previous venous thromboembolism (p=0·014), being bedbound in the past 12 weeks for any reason (p=0·003), and lower limb oedema (p=0·009) independently predicted deep vein thrombosis. Serum albumin concentration (p=0·43), thromboprophylaxis (p=0·17), and survival (p=0·45) were unrelated to deep vein thrombosis. INTERPRETATION: About a third of patients with advanced cancer admitted to SPCUs had a femoral deep vein thrombosis. Deep vein thrombosis was not associated with thromboprophylaxis, survival, or symptoms other than leg oedema. These findings are consistent with venous thromboembolism being a manifestation of advanced disease rather than a cause of premature death. Thromboprophylaxis for SPCU inpatients with poor performance status seems to be of little benefit. FUNDING: National Institute for Health Research (Research for Patient Benefit programme).
引用
- White C, Noble SIR, Watson M, et al. Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study. Lancet Haematol. 2019. PMID: 30709436. doi:10.1016/S2352-3026(18)30215-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。